HOW TO MANAGE POSTMENOPAUSAL OSTEOPOROSIS?BODY, J. J.Acta clinica belgica (English ed.). 2011, Vol 66, Num 6, pp 443-447, issn 1784-3286, 5 p.Conference Paper

Marqueurs du remodelage et ostéopathies malignesBODY, J. J.La Lettre du rhumatologue. 2008, Num 344, pp 39-39, issn 0761-5027, 1 p.Article

Traitement de l'ostéoporose post-ménopausique : actualités et perspectives = Update on treatment of postmenopausal osteoporosisBODY, J.-J.Revue médicale de Bruxelles. 2008, Vol 29, Num 4, pp 301-309, issn 0035-3639, 9 p.Conference Paper

Management of primary osteoporosisBODY, J.-J.Acta Clinica Belgica. 2002, Vol 57, Num 5, pp 277-283, issn 0001-5512, 7 p.Article

Traitement de l'ostéoporose: actualisation et perspectives = Treatment of osteoporosis: current status and perspectivesBODY, J.-J.Revue médicale de Bruxelles. 1994, Vol 15, Num 4, pp 282-286, issn 0035-3639Article

Marqueurs du remodelage et ostéopathies malignesBODY, J. J.Métabolismes, hormones, diabètes et nutrition. 2008, Vol 12, Num 4-5, pp 188-188, issn 1762-3065, 1 p.Article

Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone diseaseBODY, J.-J.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 5, pp 5-8, issn 1359-6349, 4 p.Article

Calcitonin : from the determination of circulating levels in various physiological and pathological conditions to the demonstration of lymphocyte receptorsBODY, J. J.Hormone research. 1993, Vol 39, Num 3-4, pp 166-170, issn 0301-0163Conference Paper

Tumor bone diseaseBODY, J.-J.Annales d'endocrinologie. 2006, Vol 67, Num 2, pp 166-172, issn 0003-4266, 7 p.Conference Paper

Ostéopénie et ostéoporose : Epidémiologie, coût, efficacité des méthodes diagnostiques et progrès thérapeutiques récents = Osteopenia and osteoporosis : Epidemiology, cost, effectivenessof diagnostic method and new therapeutical progressBODY, J.-J.Radiologie (Berlin). 1998, Vol 18, Num 2, pp 167-170, issn 0720-3322Article

Les hypercalcémies des tumeurs solides : physiopathologie et traitement = Hypercalcemia of solid tumors: physiopathology and treatmentBODY, J.-J.Revue française d'endocrinologie clinique, nutrition et métabolisme. 1992, Vol 33, Num 3, pp 201-208, issn 0048-8062Article

Cancer hypercalcemia: recent advances in understanding and treatmentBODY, J.-J.European journal of cancer & clinical oncology. 1984, Vol 20, Num 7, pp 865-869, issn 0277-5379Article

Le traitement de la maladie osseuse de paget par l'acide zolédronique = Treatment of Paget's disease of bone with zoledronic acidBODY, J. J; STERNON, J.Revue médicale de Bruxelles. 2005, Vol 26, Num 6, pp 513-517, issn 0035-3639, 5 p.Article

Raloxifene (Celvista®, Evista®) = RaloxifeneBODY, J. J; STERNON, J.Revue médicale de Bruxelles. 2000, Vol 21, Num 1, pp 35-41, issn 0035-3639Article

Assessment of dyspnea in advanced cancer patientsMANCINI, I; BODY, J. J.Supportive care in cancer. 1999, Vol 7, Num 4, pp 229-232, issn 0941-4355Conference Paper

Bisphosphonates influence the proliferation and the maturation of normal human osteoblastsFROMIGUE, O; BODY, J. J.Journal of endocrinological investigation (Testo stampato). 2002, Vol 25, Num 6, pp 539-546, issn 0391-4097Article

Nutrition and quality of life in cancer patientsBODY, J. J; BORKOWSKI, A.European journal of cancer & clinical oncology. 1987, Vol 23, Num 2, pp 127-129, issn 0277-5379Article

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastasesBEUSELINCK, B; WOLTER, P; POPPEL, H. Van et al.British journal of cancer. 2012, Vol 107, Num 10, pp 1665-1671, issn 0007-0920, 7 p.Article

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubBODY, J.-J; BERGMANN, P; BOONEN, S et al.Osteoporosis international. 2010, Vol 21, Num 10, pp 1657-1680, issn 0937-941X, 24 p.Article

A prospective study on hyponatraemia in medical cancer patients : epidemiology, aetiology and differential diagnosisBERGHMANS, T; PAESMANS, M; BODY, J.-J et al.Supportive care in cancer. 2000, Vol 8, Num 3, pp 192-197, issn 0941-4355Conference Paper

Calcitonin deficiency in primary hypothyroidismBODY, J.-J; DEMEESTER-MIRKINE, N; BORKOWSKI, A et al.The Journal of clinical endocrinology and metabolism. 1986, Vol 62, Num 4, pp 700-703, issn 0021-972XArticle

A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnoverRINGE, J. D; BODY, J.-J.Clinical and experimental rheumatology (Testo stampato). 2007, Vol 25, Num 5, pp 766-774, issn 0392-856X, 9 p.Article

Current and future directions in medical therapy : HypercalcemiaBODY, J.-J.Cancer. 2000, Vol 88, Num 12, pp 3054-3058, issn 0008-543X, SUPConference Paper

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionPECHERSTORFER, M; LUDWIG, H; SCHLOSSER, K et al.Journal of bone and mineral research (Print). 1996, Vol 11, Num 5, pp 587-593, issn 0884-0431Article

Calcitonin secretion in idiopathic renal stone formersFUSS, M; PEPERSACK, T; CORVILAIN, J et al.Journal of bone and mineral research (Print). 1991, Vol 6, Num 1, pp 35-38, issn 0884-0431Article